pop up description layer
  lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++ lauftext +++  
 
Symposia contacts
Hall overview
Organisation guideOrganisation guide
Industry Meeting RoomsTechnical details
Promotional servicesPromotional services
Industry meeting roomsIndustry meeting rooms
 
 
 
 
 
EASD Registration Scientific Programme
Congrex

 

 Back to Symposia overview

STEERING A COURSE THROUGH THE COMPLEXITIES OF TYPE 2 DIABETES

Monday, 20 September 2010, 14:30 – 17:00
De Duve Hall

Chairs: Julio Rosenstock, US and Michael Nauck, DE  
14:30 – 14:40 Welcome and introduction
Julio Rosenstock, US		  
14:40 – 15:00 Personalized medicine in type 2 diabetes: practical target or unattainable goal?
Antonio Ceriello, ES		  
15:00 – 15:20 The coming of age of incretin-based therapies
Michael Nauck, DE		  
15:20 – 15:40 Metformin fails... what‘s next?
Steven Kahn, US		  
15:40 – 16:00 Kidney disease in type 2 diabetes: how much does it really matter?
Per-Henrik Groop, FI		  
16:00 – 16:20 Lowering blood glucose effectively with a novel DPP-4 inhibitor
Julio Rosenstock, US		  
16:20 – 16:40 Latest developments: the future for type 2 diabetes treatment
Ele Ferrannini, IT		  
16:40 – 17:00 Interactive panel discussion and close
All / Michael Nauck, DE		  

 

Sponsor: Boehringer Ingelheim  
 
 print this page  
         
 
© 2010 EASD | Contact | Imprint

ExhibitionSymposia General